Professor Syed Hussain

MBBS, MSc, MD, FRCP

Department of Oncology and Metabolism

Professor and Consultant in Medical Oncology

syed.hussain@sheffield.ac.uk
+44 114 215 9021

Full contact details

Professor Syed Hussain
Department of Oncology and Metabolism
Room 228, 2nd Floor, Broomcross Building
Weston Park Hospital
Whitham Road
Sheffield
S10 2SJ
Profile

I graduated from Dow Medical College Karachi in 1994 and completed my general medical professional training in UK. I did my Doctorate in Oncology at the University of Birmingham and then completed my Medical oncology training in Birmingham, United Kingdom and received my certification and specialist registration in Medical oncology.

I am Professor and Consultant in Medical Oncology at the University of Sheffield and Sheffield Teaching Hospitals NHS Trust.

Research interests

My major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. I have set up a large number of clinical trials from early phase to late phase studies during my career.

My work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001), to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012).

This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment. I am principal investigator of a number of studies in urological cancers.

I am chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study in muscle invasive bladder cancer and have served as chief investigator of various early phase trials, and translational studies.

I have authored over 90 peer-reviewed publications including 4 book chapters in textbooks of oncology and been an invited speaker to a number of national and international meetings. I have secured funding of over 10 million pounds from funding bodies.


Current Projects

  • Setting up of clinical trials in bladder cancers.
  • Early phase studies in bladder cancer.
  • Development of panel of Biomarkers in bladder cancer.
  • Translational research linked to bladder cancer clinical trials.
Publications

Journal articles

Chapters

  • Hussain S & James ND (2013) A multidisciplinary approach in muscle-invasive disease In Hussain S (Ed.), American Society Clinical Oncology Education Book RIS download Bibtex download
  • Hussain S & Palmer DH (2013) Systematic chemotherapy for liver tumours In Fong , Poon , Tang , Dupuy & Berlin (Ed.), Hepatobiliary Cancer RIS download Bibtex download
  • Hussain S, James ND, Bryan R, Patel P & Viney R (2012) Bladder cancer, in Perez and Brady's Principles and Practice of Radiation Oncology In Halperin EC, Wazer DE, Perez CA & Brady LW (Ed.), Percy and Brady textbook of radiation oncology RIS download Bibtex download
  • Hussain S, Zarkar A & James N (2008) Concomitant chemo-radiotherapy principles and management In Price (Ed.), Treatment of Cancer RIS download Bibtex download

Conference proceedings papers

  • Hussain SA (2019) Changing Landscape in the Management of Advanced Bladder Cancer. JOURNAL OF PATHOLOGY, Vol. 249 (pp S10-S10) RIS download Bibtex download
  • Porta N, Song YP, Hall E, Choudhury A, Owen R, Lewis R, Hussain S, James ND, Huddart RA & Hoskin P (2019) Hypo-Fractionation in Muscle-Invasive Bladder Cancer: An Individual Patient Data (IPD) Meta-Analysis of the BC2001 and BCON Trials. International Journal of Radiation Oncology*Biology*Physics, Vol. 105(1) (pp S138-S138) RIS download Bibtex download
  • Powles T, Wheater MJ, Din O, Geldart TR, Boleti E, Stockdale A, Sundar S, Robinson A, Ahmed I, Sarker S-J , Hussain SA et al (2015) A randomized phase II study of AZ2014 versus everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC).. Journal of Clinical Oncology, Vol. 33(7_suppl) (pp 409-409) RIS download Bibtex download
  • James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(18) RIS download Bibtex download
  • James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15) RIS download Bibtex download
Teaching interests

I regularly taught pharmacology to both undergraduate and postgraduate students in my previous roles and supervised both MSc and PhD students in both their projects and research.

Professional activities
  • Association of Cancer Physicians (ACP)
  • European Society of Medical Oncology (ESMO)
  • American Society of Clinical Oncology (ASCO)
  • NCRI Blader & Renal Clinical studies group
  • British Medical Association
  • Chair of the NCRI Advanced Bladder Cancer – subgroup